RetaMax 60mg (GLP-3): Educational Research, Mechanism & Safety

RetaMax 60mg (GLP-3) appears to be a product-style name associated with retatrutide, an investigational compound developed by Eli Lilly. I could not verify from reliable sources that “RetaMax 60mg” is an official pharmaceutical product or an approved retatrutide formulation, so it is safest to treat the name as a marketing/product label rather than an established medicine.

Retatrutide itself is more accurately described as a GIP/GLP-1/glucagon triple receptor agonist. “GLP-3” is an informal and scientifically inaccurate nickname.

What Is RetaMax 60mg (GLP-3)?

Retatrutide, also known as LY3437943, is an investigational medicine being studied for obesity and several metabolic conditions.

Its mechanism involves activation of three receptors:

• GIP
• GLP-1
• Glucagon

This three-pathway mechanism distinguishes retatrutide from medicines that act primarily through one or two incretin pathways.

What Does “RetaMax 60mg (GLP-3)” Mean?

The 60mg designation appears to describe the amount stated on a particular product label. However, it should not be interpreted as an FDA-approved retatrutide dose.

Clinical studies have evaluated retatrutide at substantially lower investigational doses, and there is currently no FDA-approved dose.

Therefore, educational content should avoid presenting “60mg” as a recommended treatment dose.

Why Is RetaMax 60mg (GLP-3) Called GLP-3?

The term GLP-3 sometimes appears in online discussions because retatrutide affects three hormonal pathways.

However, Lilly explicitly explains that “GLP-3” is scientifically inaccurate. Retatrutide does not act on a GLP-3 receptor. Triple agonist is the more accurate description.

RetaMax 60mg (GLP-3) and Weight-Loss Research

Retatrutide has generated considerable interest because clinical trials have reported substantial reductions in body weight.

In the Phase 3 TRIUMPH-1 study, the highest studied dose produced an average 28.3% reduction in body weight at 80 weeks among adults with obesity or overweight and a weight-related condition who did not have diabetes.

Additional Phase 3 results announced in July 2026 also showed substantial weight reduction in people with obesity or overweight and type 2 diabetes and in people with severe obesity and cardiovascular disease.

These results come from controlled clinical research and should not be interpreted as evidence that an independently marketed product called RetaMax 60mg will produce the same results.

RetaMax 60mg (GLP-3) Other Research Areas

Retatrutide is being studied in several areas, including:

• Obesity
• Type 2 diabetes
• Cardiovascular outcomes
• Obstructive sleep apnea
• Knee osteoarthritis
• Chronic low-back pain
• Metabolic dysfunction-associated steatotic liver disease

Lilly continues to evaluate retatrutide in Phase 3 clinical trials.

Is RetaMax 60mg FDA Approved?

No verified FDA approval exists for RetaMax 60mg.

More broadly, retatrutide itself is not currently FDA approved. Lilly describes it as investigational and says it is legally available only through its clinical trials.

Recent reporting has also highlighted the risks associated with unapproved retatrutide products being marketed online.

Safety Considerations

Because retatrutide remains investigational, its long-term safety profile continues to be evaluated.

Products marketed outside regulated clinical research may introduce additional concerns, including:

• Unknown purity
• Incorrect ingredient concentration
• Contamination
• Mislabeling
• Unknown impurities
• Variable manufacturing quality
• Uncertain long-term effects

Lilly specifically warns that unapproved products claiming to contain retatrutide may contain the wrong ingredient, contaminants, or inaccurate amounts of active substance.

Frequently Asked Questions

What is RetaMax 60mg?

RetaMax 60mg appears to be a product-style name associated with retatrutide, but I could not verify it as an FDA-approved pharmaceutical product.

Is RetaMax the same as retatrutide?

The name suggests an association with retatrutide, but the identity, composition, purity, and concentration of an independently marketed product cannot be established simply from its name.

Is retatrutide a GLP-3?

No. “GLP-3” is an informal nickname. Retatrutide is a GIP/GLP-1/glucagon triple agonist.

Is retatrutide FDA approved?

No. Retatrutide remains investigational and is currently being evaluated in clinical trials.

Is 60mg an approved retatrutide dose?

No. There is currently no FDA-approved retatrutide dose, and a 60mg product label should not be presented as a therapeutic recommendation.

Conclusion

RetaMax 60mg (GLP-3) is best treated as a product/SEO keyword rather than an established pharmaceutical name. Retatrutide, the compound it appears to reference, is an investigational GIP/GLP-1/glucagon triple agonist with promising clinical-trial results in obesity and metabolic research.

However, “GLP-3” is not scientifically accurate, RetaMax 60mg is not verified as an approved pharmaceutical product, and retatrutide itself remains unapproved.

Educational disclaimer: This article is for educational and SEO purposes only. It is not medical advice and does not provide dosing, preparation, administration, purchasing, or treatment instructions.